Say NO to Novartis!March 19, 2012 Novartis, the Swiss-based pharmaceutical giant, continues its assault on India's generic pharmaceutical industry -- legally challenging India's patent law that allows the nation to supply nearly 80% of the developing world's access to high-quality, affordable, life-saving medications. India's patent law effectively stops evergreening, a tactic used by pharmaceutical companies to make minor tweaks on medications to extend their stranglehold on a patent that is about to expire. Should Novartis succeed on March 28th, a dangerous precedent will be set ... With a chain-reaction of serious consequences. The costs? Crippling the generic pharmaceutical industry Making essential medications even more cost-prohibitive Cutting off the supply of medications used by NGO's worldwide Millions of lives that are dependent on these drugs to fight diseases like HIV/AIDS. Send the message to Novartis that no loss of human life can ever be tolerated for profits, by signing a petition here. Learn more on how to Occupy Pharma by joining our working group. This article was provided by HIV Prevention Justice Alliance. Visit HIV Prevention Justice Alliance's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|